Skip to main content
Quest Diagnostics

Cost Effectiveness of Population-Level Preventative Genetic Screening for Underdiagnosed Hereditary Conditions and Implications for Implementation by Health Systems

ACHE 2024 Congress on Healthcare Leadership

American College of Healthcare Executives

Chicago, IL March 25 - 28, 2024

Poster presentation: Cost Effectiveness of Population-Level Preventative Genetic Screening for Underdiagnosed Hereditary Conditions and Implications for Implementation by Health Systems

Authors: Burton RA, South S, Champine M,  Serra R

Specialty: Genetics, Oncology

Related content

Conference Presentation
Cost Savings of Implementing a Higher Validated Dilution of Serum Folate
Publication
Strategies to Drive Effective Laboratory Test Utilization

Our company

Quest® is the brand name used for services offered by Quest Diagnostics Incorporated and its affiliated companies. Quest Diagnostics Incorporated and certain affiliates are CLIA-certified laboratories that provide HIPAA-covered services.  Other affiliates operated under the Quest® brand, such as Quest Consumer Inc., do not provide HIPAA-covered services. 

 

Quest®, Quest Diagnostics®, any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third-party marks—® and ™—are the property of their respective owners. © 2025 Quest Diagnostics Incorporated. All rights reserved. Image content features models and is intended for illustrative purposes only.